IN2014MN02252A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02252A
IN2014MN02252A IN2252MUN2014A IN2014MN02252A IN 2014MN02252 A IN2014MN02252 A IN 2014MN02252A IN 2252MUN2014 A IN2252MUN2014 A IN 2252MUN2014A IN 2014MN02252 A IN2014MN02252 A IN 2014MN02252A
Authority
IN
India
Prior art keywords
present
aids
manufacturing
treatment
particularly useful
Prior art date
Application number
Other languages
English (en)
Inventor
Shrinivas Madhukar Purandare
Geena Malhotra
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to IN2252MUN2014 priority Critical patent/IN2014MN02252A/en
Publication of IN2014MN02252A publication Critical patent/IN2014MN02252A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2252MUN2014 2012-05-03 2013-05-03 IN2014MN02252A (OSRAM)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN2252MUN2014 IN2014MN02252A (OSRAM) 2012-05-03 2013-05-03

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1380MU2012 2012-05-03
IN2590MU2012 2012-09-06
PCT/GB2013/000193 WO2013164559A1 (en) 2012-05-03 2013-05-03 Antiretroviral composition
IN2252MUN2014 IN2014MN02252A (OSRAM) 2012-05-03 2013-05-03

Publications (1)

Publication Number Publication Date
IN2014MN02252A true IN2014MN02252A (OSRAM) 2015-07-24

Family

ID=48468655

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2252MUN2014 IN2014MN02252A (OSRAM) 2012-05-03 2013-05-03

Country Status (13)

Country Link
US (1) US20150086628A1 (OSRAM)
EP (1) EP2844231A1 (OSRAM)
JP (1) JP6314131B2 (OSRAM)
KR (1) KR20150021510A (OSRAM)
CN (1) CN104411300A (OSRAM)
AU (1) AU2013255666A1 (OSRAM)
CA (1) CA2871794A1 (OSRAM)
IN (1) IN2014MN02252A (OSRAM)
JO (1) JO3641B1 (OSRAM)
MX (1) MX2014013326A (OSRAM)
RU (1) RU2014148964A (OSRAM)
WO (1) WO2013164559A1 (OSRAM)
ZA (1) ZA201408281B (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2663466C1 (ru) * 2017-03-20 2018-08-06 Общество с ограниченной ответственностью "МБА-групп" Композиция для профилактики и/или лечения вич-инфекции
CN112220771B (zh) * 2020-11-10 2023-03-31 成都大学 扎西他滨渗透泵型控释片及其制备方法
EP4479092A1 (en) * 2022-02-14 2024-12-25 Purdue Research Foundation Polymer salts for improved drug delivery from amorphous solid dispersions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226822A (en) * 1987-11-16 1990-03-27 Mcneil Consumer Prod Chewable medicament tablet containing means for taste masking
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
JP3693270B2 (ja) * 1995-10-12 2005-09-07 旭化成ケミカルズ株式会社 フィルムコーティング顆粒およびその製造方法
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
EP1395249A1 (en) 2001-05-25 2004-03-10 Abbott Laboratories Soft elastic capsules comprising ritonavir and/or lopinavir
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
CN1917860A (zh) * 2004-02-06 2007-02-21 惠氏公司 多颗粒o-去甲基文拉法辛盐及其用途
KR20070007868A (ko) * 2004-03-31 2007-01-16 비피에스아이 홀딩스, 인코포레이션. 경구 섭취 가능한 기질용 장용성 피복
PE20080422A1 (es) * 2006-08-10 2008-04-28 Cipla Ltd Composicion solida antirretroviral de administracion oral
KR20100097156A (ko) * 2007-11-16 2010-09-02 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
GT200800303A (es) * 2007-12-24 2009-09-18 Combinacion anti-retroviral
WO2009153654A1 (en) * 2008-06-17 2009-12-23 Aurobindo Pharma Limited Solid dosage forms of antiretrovirals
US20130142877A1 (en) * 2010-05-10 2013-06-06 Evonik Roehm Gmbh Pharmaceutical dosage form comprising one or more antiretroviral active ingredients
WO2013057469A1 (en) * 2011-10-20 2013-04-25 Cipla Limited Pharmaceutical antiretroviral compositions

Also Published As

Publication number Publication date
RU2014148964A (ru) 2016-06-27
AU2013255666A1 (en) 2014-11-20
WO2013164559A1 (en) 2013-11-07
CN104411300A (zh) 2015-03-11
JP6314131B2 (ja) 2018-04-18
KR20150021510A (ko) 2015-03-02
ZA201408281B (en) 2019-06-26
JP2015519326A (ja) 2015-07-09
CA2871794A1 (en) 2013-11-07
US20150086628A1 (en) 2015-03-26
JO3641B1 (ar) 2020-08-27
MX2014013326A (es) 2015-08-10
EP2844231A1 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
IL264644B (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
EP3038661A4 (en) Methods and compositions for rna-guided treatment of hiv infection
ZA201708236B (en) Methods and compositions for rna-guided treatment of hiv infection
EP3442465A4 (en) TARGETED DEPOSITION OF DENTAL CARE COMPOUNDS
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
AU2018348359A8 (en) Extended release pharmaceutical formulation and methods of treatment
MX2014011825A (es) INHIBIDORES DE ISOXAZOL ß-LACTAMASA.
IN2013MU01749A (OSRAM)
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
CY1121999T1 (el) Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
NZ738524A (en) Pharmaceutical formulations comprising rilpivirine hydrochloride, tenofovir alafenamide hemifumarate, and emtricitabine
SG179082A1 (en) Method for the preparation of an influenza virus
EP2978449A4 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
EP2601967A4 (en) MEDICINE FOR PREVENTING AND TREATING HIV-RELATED OR HIV-RELATED DISEASES, INCLUDING AIDS
MX341976B (es) Formulaciones de darunavir.
LT2939665T (lt) Farmacinė kompozicija, skirta živ infekcijų gydymui
MX374931B (es) Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina.
WO2015086738A3 (en) Hiv vaccine
IN2014MN02252A (OSRAM)
IN2015DN02296A (OSRAM)
EP3538079A4 (en) COMPOSITIONS AND METHODS FOR TREATING ORAL INFECTIOUS DISEASES
HK40114560A (en) Methods and compositions for rna-guided treatment of hiv infection